Sanofi India share news, announcements and annual reports
NSE: SANOFIBSE: 500674Pharmaceuticals & BiotechnologySmall Cap
Sanofi India Limited · Formerly Aventis Pharma · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1984 on BSE, May 2003 on NSE
Last close ₹3,204.10up ₹14.60 (0.46%)BSE ₹3,204.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,189.50.
30 Oct: open ₹3,265.00, high ₹3,422.60, low ₹3,175.10
52-week range of traded prices to 30 Oct 2026
₹2,758.20Low, 23 Oct 2026₹4,834.00High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,379 Cr614th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.24
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 3.84%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 45.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 57.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Jun 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,04,44220.0% delivered
Sanofi India share news and announcements
701 announcements, routine notices left out, newest first. Page 10 of 15.
Aug 2016
Jul 2016
22 Jul · Corporate action
Jun 2016
2 Jun · Board meeting
May 2016
12 May · Legal
Apr 2016
Mar 2016
23 Mar · Board meeting
Feb 2016
Jan 2016
Dec 2015
11 Dec · News Verification
News about Sanofi India Limited. The media had reports that "Sanofi Pasteur in talks to bring first dengue vaccine to India". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sanofi India Limited has vide its letter inter-alia stated, "We wish to clarify that the article in Business Standard refers to Sanofi Pasteur India Private Limited which is an unlisted company of the Sanofi Group and not to Sanofi India Limited, which is a listed company. Sanofi India Limited has not entered into negotiations for bringing the dengue vaccine to India."11 Dec · News Verification
Exchange has sought clarification from Sanofi India Limited, with respect to recent news item captioned "Sanofi Pasteur in talks to bring first dengue vaccine to India". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Nov 2015
Oct 2015
30 Oct · News Verification
News about Sanofi India Limited. The media had reports that "Setback For Glenmark: Sanofi Not To Pursue Development Of Vatelizumab Molecule". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sanofi India Limited has vide its letter inter-alia stated, "We wish to clarify that our Company, Sanofi India Limited whose shares are listed on your Exchange, had not entered into any negotiations for development of vatelizumab molecule. Our parent company, Sanofi SA has announced , in a press release issued from Paris, France yesterday on its Q 3 2015 results, that it would not pursue development of the molecule."29 Oct · News Verification
Exchange has sought clarification from Sanofi India Limited, with respect to recent news item captioned "Setback For Glenmark: Sanofi Not To Pursue Development Of Vatelizumab Molecule". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Jul 2015
27 Jul · Management
21 Jul · Dividend
Dividend will be paid on August 12, 2015.21 Jul · Dividend
Board of Directors of the Company at their meeting held on July 21, 2015, has declared an Interim Dividend of Rs. 18 per Equity share of Rs 10.21 Jul · Results
17 Jul · Corporate action
Company has fixed Record Date as July 30, 2015 for the purpose of interim dividend.
Jun 2015
May 2015
Apr 2015
30 Apr · Disclosure of Voting Pattern - Clause 35A